Pharming Group Nv ( (PHAR) ) has released its Q2 earnings. Here is a breakdown of the information Pharming Group Nv presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases, with a strong presence in North America, Europe, and Asia-Pacific. In its latest earnings report, Pharming Group N.V. announced a significant 26% increase in total revenues for the second quarter of 2025, reaching US$93.2 million, driven by robust growth in its flagship products, RUCONEST® and Joenja®. The company reported an operating profit of US$10.8 million, a notable turnaround from a loss in the same period last year. Key financial highlights include a 28% increase in RUCONEST® revenue and a 15% rise in Joenja® revenue, alongside a substantial increase in cash and marketable securities to US$130.8 million. Pharming also raised its full-year revenue guidance to between US$335 million and US$350 million. Looking ahead, Pharming Group remains optimistic about its growth prospects, supported by ongoing strategic initiatives, including expanding its patient base for Joenja® and advancing regulatory filings for leniolisib in Japan and other markets.